ACR 2021 - Lupus Congress Preview Brochure

ACR 2021
CONGRESS PREVIEW
Developed under the auspices of:
Supported with educational grant from:

Lupus Highlights from ACR 2021
Chairman’s Introduction
Dear Colleagues
Welcome to the Lupus Forum 2021 ACR Congress Preview, our first for the Lupus Forum. Our focus
in developing this preview is to highlight the key abstracts in Lupus for the busy clinician to keep
abreast of key developments in science and therapeutics.
Lupus is featured in a number of plenary sessions starting with Plenary Session I on Saturday
looking at disparities in care (Abs 454). Saturday also sees an oral presentation on BT-104, a novel
oral therapy that enhanced regulatory T cell function, in the SLE Animal Models session (471). There
are also several interesting posters on Saturday, which can be found in the Diagnosis and
Manifestations section and the Health Service Research section.
Plenary Session II on Sunday includes a discussion on flare risk in a multinational inception cohort
presented by Sasha Bernatsky (959). There are a couple of highlighted posters in the Animal Models
section in Poster Session B, which look at potential therapies (535, 537), and there are several
highlighted posters in the Diagnosis, Management and Outcomes section.
Monday sees two plenary talks featuring Voclosporin (1425) and the dual BAFF/APRIL inhibitor
ALPN-303 (1429). The New Agents, Old Agents session includes abstracts on Iberdomide (1458);
Anifrolumab (1459); Belimumab (1461) and HCQ dose and flare (1462). There are several
interesting poster sessions and we have highlighted some posters in the Patient Preferences,
Diagnosis and Outcomes sections
While there is no highlighted oral presentation on Tuesday there is an abundance of posters in the
SLE Treatment section in Poster Session D. These include current biologics Belimumab (1736,
1737, 1754, 1757, 1761) and Anifrolumab (1736, 1740, 1741, 1742; established small molecules
Mycophenolate (1745), Glucocorticoids (1735, 1760) and Hydroxychloroquine (1753, 1768). New
and developing therapies are also featured with Voclosporin (1751,1752) and Baricitinib (1746,
1763) along with early studies of Efavaleukin Alfa (1734), BIIB059 (1747) and Itolizumab (1750)
We will be adding new content to the Lupus Forum every month so please log in to ensure you get
all the updates on therapies in Lupus. You can also follow us on Twitter @LupusForum and on
LinkedIn by searching “Lupus Forum” or www.linkedin.com/in/lupusforum.
I hope you find our selection of highlights useful, and that you enjoy the ACR Convergence meeting.
Kind regards
Ed Vital
Associate Professor
University of Leeds
lupus-forum.com ACR 2021 Preview 1

Key Presentations
Saturday 6 th November 2021
11:00–11:15 PLENARY SESSION I
454
Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities
by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
11:00–12:00 ORAL ABSTRACT SESSION
SLE – Animal Models
471
Therapeutic Efficacy of BT-104, an Oral LANCL2 Agonist, for the Treatment of
Systemic Lupus Erythematosus
08:30–10:30 POSTER SESSION A
Health Services Research Poster I: Lupus, Inflammatory Arthritis, and more
130
135
Clinical and Economic Characterization of Systemic Lupus Erythematosus
Patients: Real World Observation Across Disease Severity and Payer Channels
in the U.S
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic
Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally
Managed Depression to Those with Sub-optimally Managed Depression
SLE – Diagnosis, Manifestation & Outcomes Poster I: Diagnosis
329
Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE
Diagnosis in a Multi-Ethnic Cohort
347 Longitudinal ANA Titers in SLE and ANA+ Controls
348
349
351
The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term
Outcomes
Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus
Erythematosus in a Predominantly African American Cohort
Gene Signature Fingerprints Divide SLE Patients in Subgroups with Similar
Biological Disease Profiles: A Multicenter Longitudinal Study
lupus-forum.com ACR 2021 Preview 2

Sunday 7 th November 2021
11:15–11:30 PLENARY SESSION II
Impact of Systemic Lupus Disease Activity State on Flare Risk After
959 Hydroxychloroquine Maintenance, Reduction or Discontinuation in a
Multinational Inception Cohort
08:30–10:30 POSTER SESSION B
SLE – Animal Models Poster
535
537
Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus
Erythematosus (SLE)
The Clinical, Oral Small Molecule IRAK4 Inhibitor, GS-5718, Improves Survival
and Reduces Disease Pathologies by Modulating Multiple Inflammatory
Endpoints in the Murine NZB/W Model of Spontaneous Lupus
SLE – Diagnosis, Manifestations and Outcomes Poster II: Manifestations
859
864
869
871
875
Bridging the Gap Between Patient-Reported Outcomes and Disease-Related
Outcomes in Lupus – a Feasibility Study
Does Obesity Affect Disease Activity Outcomes in Systemic Lupus
Erythematosus?
Comparison of Two Frailty Definitions in Women with Systemic Lupus
Erythematosus
The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular
Events in Patients with Systemic Lupus Erythematosus
Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ
Blood Levels and Lupus Disease Activity
877 Association of HCQ Blood Levels with Type 1 and 2 SLE Activity
878
879
Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease
Activity, Health-Related Quality of Life and Depression
Anti-dsDNA Antibodies Increase Systemic Lupus Erythematosus Cardiovascular
Risk Impairing the Immune and Cardiovascular Systems
883 Multimorbidity Burden in Systemic Lupus Erythematosus: A Nationwide Study
887
890
892
893
Association of Mycophenolate and Azathioprine Use with Cognitive Function in
SLE
Depression Is Associated with Frailty in Systemic Lupus Erythematosus Patients:
Multicenter Retrospective Analysis Using Systemic Lupus Erythematosus
International Collaborating Clinics-Frailty Index
Screening for Cognitive Impairment with the Automated Neuropsychological
Assessment Metrics in Patients with Systemic Lupus Erythematosus
Trajectories of Depressive Symptoms in Systemic Lupus Erythematosus over 7
Years
lupus-forum.com ACR 2021 Preview 3

Monday 8 th November 2021
10:45–11:00 PLENARY SESSION III
1425
Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension
Study
ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by
1429 Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE)
and Other B Cell-Related Diseases
15:30–17:00 ORAL ABSTRACT PRESENTATION
SLE- New Agents, Old Agents
1458
1459
1461
Sustained Efficacy and Safety of Iberdomide to Week 52 in Patients with Active
Systemic Lupus Erythematosus (SLE) in a Phase 2, Randomized, Placebo-
Controlled Study
Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab
in 2 Phase 3 Trials
Belimumab Improves Renal Responses in Patients with or Without Steroid
Pulses During Induction Therapy for Lupus Nephritis
1462 Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares
08:30–10:30 POSTER SESSION C
Patient Outcomes, Preferences and Attitudes Poster III
1161 Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
SLE – Diagnosis, Manifestations, & Outcomes Poster III: Diagnosis
1261
1295
The Impact of Remission and Low Disease Activity Attainment on Health-related
Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus
Erythematosus
Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across
Multiple Patient Subgroups: Results of a Large Integrated Analysis
First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard
1288 of Care Treatment: Results from the British Isles Lupus Assessment Group
Biologics Registry (BILAG-BR)
SLE – Diagnosis, Manifestations and Outcomes Poster III: Outcomes
1257
1257
The Impact of Remission and Low Disease Activity Attainment on Health-related
Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus
Erythematosus
Improvements in Abnormal Laboratory Tests Are Associated with Clinical
Outcomes in Patients with Active Systemic Lupus Erythematosus
1258 Measurement of Specific Organ Domains in Lupus Randomised Controlled Trials
1259
Association of SLE Responder Index (SRI) Attainment and Long-term Clinical
Outcomes
lupus-forum.com ACR 2021 Preview 4

1268
1273
1274
1275
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus
Erythematosus: A Comparison of Machine Learning Methods
A 12-week Aerobic Exercise Training Program in Women with Systemic Lupus
Erythematosus (SLE) Improves Fatigue, Mitochondrial Dysfunction and
Associated Interferon Gene Signature
Severe Flares Are Associated with a Poorer Health-Related Quality of Life
(HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
Digital Solution for Collection of Patient-reported Outcome Measures in Patients
with Systemic Lupus Erythematosus: A Randomised, Crossover, Agreement
Study
1276
1280
Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity
State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a
Multinational, Multicenter SLICC (Systemic Lupus International Collaborating
Clinics) Cohort
Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and
FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO)
Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus
Nephritis
1282 Classification of Disease Activity and Damage in Cutaneous Lupus
1283
1284
1290
1294
1297
1298
1300
1301
1302
Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus
Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled
Studies
One Third of Lupus Nephritis Patients Classified as Complete Responders
Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria
Validation of a Novel Lupus Multivariable Outcome Score as an Outcome
Measure for Systemtic Lupus Erythematosus Trials
Predictors of BILAG-based Outcomes in Patients with SLE: Analysis from the
Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort and
MASTERPLANS Consortium
Factors Associated with Employment and Work Disability in Patients with SLE: A
Nested Case-control Study
Clinical Characteristics of Patients with Pre-pubertal Onset SLE and Disease
Outcome Throughout Puberty: A Multicenter North American Longitudinal Study
Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus
Erythematosus
Early Increase in Circulating Memory B Cells Portends Clinical Response to
Treatment in Pooled Data from Three Phase III Trials of Belimumab
Year-3 Observational Follow-up of Belimumab Safety (Mortality and
Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week,
Randomized, Double-Blind Placebo-Controlled Safety Study
lupus-forum.com ACR 2021 Preview 5

Tuesday 9 th November 2021
08:30–10:30 POSTER SESSION D
SLE – Etiology and Pathogenesis Poster
Metabolic Alterations of Systemic Lupus Erythematosus NK Cells Determine
1488
Response to Anti-CD38 and Anti-SLAMF7 Monoclonal Antibodies
Reproductive Issues in Rheumatic Disorders Poster
1729
SLE – Treatment Poster
1732
1733
1734
1735
1736
1737
1739
1740
1741
1742
1745
1746
1747
1748
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus
Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate
(eGFR)
Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to
Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A
Systematic Review and Meta-Analysis of Randomized Controlled Trials
Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2
Phase 3 Trials by EULAR/ACR 2019 Criteria
Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in
Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study
Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus
with Prior Severe Organ Manifestation
Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in
Urinary CD23
Reduction in Urinary CD163 Is Associated with Treatment Response in the
Belimumab Lupus Nephritis Trial
SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies
in Patients with SLE from 2 Phase 3 Trials
Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics:
Post Hoc Analysis of Data from 2 Phase 3 Trials
Anifrolumab Results in Favourable Responses Regardless of SLE Disease
Duration: Post Hoc Analysis of Data from 2 Phase 3 Trials
Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE
Participating in 2 Phase 3 Trials
Pre-pregnancy Switching from Mycophenolate to Azathioprine in Patients with
Lupus Nephritis: A Retrospective Outcome Analysis
Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic
Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-
Controlled Trial
BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with
Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-
Blind, Placebo-Controlled Study
The Peroxisome Proliferator-Activated Receptor-γ (PPAR) Agonist Pioglitazone
Improves Vascular and Metabolic Dysfunction in Patients with Systemic Lupus
Erythematosus (SLE)
lupus-forum.com ACR 2021 Preview 6

1750
1751
Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus
Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation
Study
Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus
Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
1752 Efficacy of Voclosporin in Recent Onset Lupus Nephritis
1753
1754
1757
Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease
Activity and Improvements in Cardiovascular Risk Factors
Effect of Belimumab on Autoantibodies, Complement, and B-Cell Subsets in
Patients with Lupus Nephritis
Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of
Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A
Case Series
1760 Long-term Opioid Use Among Patients with Systemic Lupus Erythematosus
1761
1763
1768
Comparison of Belimumab and Standard of Care by Inverse Probability of
Treatment Weighting Analyses Based on Propensity Score in Patients with
Systemic Lupus Erythematosus in the Maintenance Phase
Baricitinib Reduces Proinflammatory Serum Cytokines in Patients with Systemic
Lupus Erythematosus
Additional Hydroxychloroquine Therapy Regulates Adipokines in Systemic Lupus
Erythematosus with Stable Disease Activity
lupus-forum.com ACR 2021 Preview 7